Skip to main content
. 2022 May 1;18(5):1413–1418. doi: 10.5664/jcsm.9898

Table 4.

Characteristics of newly diagnosed female participants with long-COVID with RLS compared with those without RLS.

Participants with Long-COVID with New RLS Participants with Long-COVID without RLS Test Statistic P Effect Size
n (%) 13 (11.3%) 102 (88.7%)
Age, mean (SD), y 46.1 (9.7) 47.1 (12.5) t(17.5) = −0.36 .73 Cohen’s d = 0.09
Hospitalized, n (%) 3 (23.1%) 16 (15.7%) χ2 (1, n = 115) = 0.08 .78 OR = 1.6 (95% CI 0.4–6.5)
Laboratory-confirmed COVID-19 positive, n (%) 11 (84.6%) 81 (79.4%) χ2 (1, n = 115) = 0.00 .94 OR = 1.4 (95% CI 0.3–6.9)
Sleep apnea device ownership, n (%) 2 (15.4%) 6 (5.9%) χ2 (1, n = 115) = 0.48 .49 OR = 2.9 (95% CI 0.5–16.2)
High STOP-BANG score, n (%) 3 (23.1%) 36 (35.3%) χ2 (1, n = 115) = 0.32 .57 OR = 0.5 (95% CI 0.1– 2.1)
High sleep apnea risk, n (%)a 4 (30.8%) 37 (36.3%) χ2 (1, n = 115) = 0.01 .93 OR = 0.8 (95% CI 0.2– 2.7)
Neuropathic pain severity, mean (SD) 5.9 (3.0) 4.4 (3.3) t(16.0) = 1.6 .12 Cohen’s d = 0.47
Fatigue, mean (SD) 45.5 (9.6) 34.2 (10.9) t(16.2) = 0.45 .66 Cohen’s d = 1.1
Quality of life, mean (SD) 35.4 (20.2) 40.6 (21.8) t(15.8) = −0.87 .40 Cohen’s d = 0.25
Antihistamine use, n (%) 8 (61.5%) 60 (58.8%) χ2 (1, n = 115) = 0.00 1.0 OR = 1.1 (95% CI 0.3–3.7)
Antidepressant use, n (%) 3 (23.1%) 18 (17.6%) χ2 (1, n = 115) = 0.01 .92 OR = 1.4 (95% CI 0.3–5.6)
Vitamin D, n (%) 9 (69.2%) 76 (74.5%) χ2 (1, n = 115) = 0.00 .94 OR = 0.8 (95% CI 0.2–2.7)
Benzodiazepine use, n (%) 1 (7.7%) 21 (20.6%) χ2 (1, n = 115) = 0.55 .46 OR = 0.3 (95% CI 0.03–2.6)
Steroid use, n (%) 3 (23.1%) 27 (26.5%) χ2 (1, n = 115) = 0.00 1.0 OR = 0.83 (95% CI 0.2–3.2)

a“High sleep apnea risk” denotes those who own a sleep apnea device and/or have a STOP-BANG score ≥ 3. CI = confidence interval, COVID-19 = coronavirus disease 2019, OR = odds ratio, RLS = restless legs syndrome. SD = standard deviation.